Dana Insulin Pump

Diabetes Technology

Insulin Pumps Next Infusion Sets Next Meters & Monitors Next Software Next Presentations


Meters & Monitors

Blood Glucose Meters Next Current Continuous Monitors Next Future Continuous Monitors Next Improving Today's Meters


Future Monitoring

A.Menarini Diagnostics Next Animas Glucose Sensor Next Cybiocare OHD Next Fovioptics Next InLight Solutions Next Integrated Applications Next Kumetrix Next LighTouch Medical Next NIR Diagnostics Next Optiscan Next RetiTech Next Oxygen Biotherapeutics Next Sensors For Medicine and Science Next Sensys Medical Next Sentek Next Solianis Next Sontra Next SpectRx Next Visual Pathways


Insurance Coverage Problems

Your insurance company is unlikely to pay for a continuous monitoring device until these devices show a benefit to users. This 2001 policy statement from Blue Cross in Canada says: "There has been minimal published data regarding the potential clinical applications of the device, i.e. whether or not the more frequent measures of glucose ultimately result in improved diabetic management, as evidenced either by an alteration in anti-diabetic medications, or an improvement in hemoglobin A1c levels. Additionally, there is no published data regarding which diabetic patients may benefit most from more intense monitoring. Only one pilot study of nine patients has been published which reported that diabetic management based on information from a CGMS resulted in improved HbA1c levels, while the total insulin requirement remained constant. The most common changes in diabetic management were alteration in diet and changes in insulin schedule." Blue Cross lists continuous glucose monitoring system (CGMS) as "INVESTIGATIONAL/NOT MEDICALLY NECESSARY."

Infrared Technology Next Radio Wave Technology Next Monitoring Today Next Insurance Coverage